rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2014-99-101rsp-1365Research ArticleСтатьиArticlesОпыт применения ингибитора интерлейкина 1β канакинумаба у больного с хронической тофусной подагройEXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUTЕлисеевМ.С.EliseevMaksim Sergeyevnaelicmax@ramber.ruЖелябинО.В.ZhelyabinO Velicmax@ramber.ruБарсковаВ. Г.BarskovaV Gelicmax@ramber.ruНасоновЕвгений ЛьвовичNasonovE Lelicmax@ramber.ruФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой РАМН», Москва, РоссияРоссияV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, RussiaRussian Federation20142603201452199101Copyright © Елисеев М.S., Желябин О.V., Барскова В.Г., Насонов Е.Л., 20142014Елисеев М., Желябин О., Барскова В.Г., Насонов Е.Л.Eliseev M.S., Zhelyabin O.V., Barskova V.G., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1365

Статья посвящена клиническому опыту применения канакинумаба (Иларис®), ингибитора интерлейкина 1β, у больного хронической тофусной подагрой, резистентной к терапии нестероидными противовоспалительными препаратами, глюкокортикоидами и колхицином. Результаты свидетельствуют о хорошем, продолжительном клиническом эффекте препарата, заключающемся в уменьшении числа болезненных и припухших суставов, отсутствии обострений артрита при подборе антигиперурикемической терапии.

This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with chronic tophacaceous gout resistant to therapy with nonsteroidal anti-inflammatory drugs, glucocorticoids, and colchicine. The results show a good and long-term clinical effect of the drug, which includes reduction of the number of painful and swollen joints and the absence of exacerbations during trial of the therapy of hyperuricemia.

подаграканакинумабартритмочевая кислотаgoutcanakinumabarthritisuric acidReferences<div><p>Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–74.</p><p>Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–12. DOI: 10.1136/ard.2010.128454.</p><p>Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103. DOI: 10.1186/1471-2474-12-103.</p><p>Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012;50(6):15–8. [Barskova VG, Eliseyev MS, Denisov IS. Yhe rate of metabolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Rheumatology Science and Practice. 2012;50(6):15–8.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1287.</p><p>Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Med. 2010;26(12):2813–21. DOI: 10.1185/03007995.2010.533647.</p><p>Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31(12):2429–32.</p><p>Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22(5):908–14.</p><p>So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum. 2010;62(10):3064–76. DOI: 10.1002/art.27600.</p><p>Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48. DOI: 10.1136/annrheumdis-2011-200908.</p><p>Sunkureddi P, Bardin T, Alten R, et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3. Ann Rheum Dis. 2012;71(Suppl 3):447. DOI: 10.1136/annrheumdis-2011-200908.</p></div><br /><div><p>Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–74.</p><p>Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–12. DOI: 10.1136/ard.2010.128454.</p><p>Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103. DOI: 10.1186/1471-2474-12-103.</p><p>Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012;50(6):15–8. [Barskova VG, Eliseyev MS, Denisov IS. Yhe rate of metabolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Rheumatology Science and Practice. 2012;50(6):15–8.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1287.</p><p>Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Med. 2010;26(12):2813–21. DOI: 10.1185/03007995.2010.533647.</p><p>Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31(12):2429–32.</p><p>Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22(5):908–14.</p><p>So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum. 2010;62(10):3064–76. DOI: 10.1002/art.27600.</p><p>Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48. DOI: 10.1136/annrheumdis-2011-200908.</p><p>Sunkureddi P, Bardin T, Alten R, et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3. Ann Rheum Dis. 2012;71(Suppl 3):447. DOI: 10.1136/annrheumdis-2011-200908.</p></div><br />

The authors declare that there are no conflicts of interest present.